Recombinant Antibodies: Covagen AG presents the Fynomer technology

Speaker: Dr. Simon Brack, Head of Lead Discovery, Covagen AG, Zürich, Switzerland

Topic: Fynomers Neutralizing IL-17A: Making Use of Fc fusion protein

We will present the versatility and broad applicability of the Fynomer technology. As an example, the isolation and characterization of high-affinity Fynomers capable of neutralizing IL-17 will be shown. Furthermore, engineered Fynomer-Fc fusion proteins having appropriate physico-chemical and in vivo half-life properties are attractive drug candidates for pre-clinical and clinical development.

For more info about the event please visit www.informaglobalevents.com/event/antibodies